Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Glaukos ( (GKOS) ) has provided an update.
Glaukos Corporation’s latest investor presentation highlights significant advancements in their interventional glaucoma treatments, particularly the iDose TR therapy designed to improve patient compliance with glaucoma medications. In 2024, the company achieved milestones such as expanding their trained surgeon pool and securing coverage for their therapies; key objectives for 2025 include increasing market access and furthering clinical evidence for their innovative products.
More about Glaukos
Glaukos Corporation is an innovative company focused on developing advanced solutions for chronic eye diseases. They specialize in micro-scale surgical devices and sustained-release pharmaceuticals, with a market focus on glaucoma, ocular cancer, and other anterior and posterior segment diseases.
YTD Price Performance: 1.46%
Average Trading Volume: 573,340
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $8.63B
For an in-depth examination of GKOS stock, go to TipRanks’ Stock Analysis page.
